Patients with moderate risk are more than 50 and less than 64 years old, present 1–2 cardiovascular risk factors (smoking, dyslipidemia, insulin resistance, obesity), are treated with modest dose of AC (doxorubicin 200–400 mg/m2, epirubicin 300–600 mg/m2), with AC before trastuzumab, or are treated with one of the following classes of drugs: vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKI), Second- and third-generation Bcr-Abl TKI, Proteasome inhibitors, Combination immune checkpoint inhibitors. The gene discussed is VEGFA; the disease is Obesity.